MedTech company Baxter International has introduced its next-generation airway clearance system, Vest advanced pulmonary experience (APX) system.
Unveiled at the North American Cystic Fibrosis Conference in Phoenix, Arizona, the Vest APX System aids daily therapy for individuals with chronic lung conditions and retained secretions.
The system includes the airflow technology from the previous version but with improved comfort and additional features. It received US Food and Drug Administration (FDA) 510(k) approval earlier this year.
The Vest APX System provides airway clearance therapy when a physician chooses external manipulation of the thorax.
It is indicated for retained secretions, difficulty in secretion clearance, or atelectasis due to mucus plugging. Additionally, the system promotes airway clearance and enhances bronchial drainage for mucus collection for diagnostic purposes.
This system is suitable for patients aged six months and older, extending to the geriatric population. It is expected to be available for order this fall.
The Vest APX System uses the High Frequency Chest Wall Oscillation (HFCWO) technology to dislodge mucus from bronchial walls.
Available in a range of colours and designs, Vest APX features patented technology along with several new enhancements for improved patient experience.
It is said to offer added comfort with a lightweight garment that allows freedom of movement. Besides, the system is made from wicking fabric to keep patients cool and features a Velcro closure for an optimal fit.
The system has a touchscreen navigation that allows patients and caregivers to start therapy with just one button.
According to Baxter, the control unit is 19% smaller and 30% lighter than the previous version and comes with a convenient carrying case.
Additionally, the CARE Connex Program provides ongoing support, connecting patients and care teams with Baxter clinical experts throughout the care journey.
Baxter Front Line Care president Jim O’Connell said: “Many patients who are prescribed this therapy use it multiple times a day, every day.
“With that in mind, it was very important for us to design a solution that fits seamlessly into a patient’s daily routine.”
Baxter forayed into the non-invasive respiratory health market in December 2021 by acquiring Hillrom for approximately $12.5bn. Hillrom offers a range of respiratory health products, including airway clearance and non-invasive ventilation solutions.
Last month, Baxter’s signed a deal to divest its kidney-care segment to private equity firm Carlyle Group in a deal worth $3.8bn.
